Robust Optimal Design for the Estimation of Hyperparameters in Population Pharmacokinetics

The expectation of the determinant of the inverse of the population Fisher information matrix is proposed as a criterion to evaluate and optimize designs for the estimation of population pharmacokinetic (PK) parameters. Given a PK model, a measurement error model, a parametric distribution of the parameters and a prior distribution representing the belief about the hyperparameters to be estimated, the EID criterion is minimized in order to find the optimal population design. In this approach, a group is defined as a number of subjects to whom the same sampling schedule (i.e., the number of samples and their timing) is applied. The constraints, which are defined a priori, are the number of groups, the size of each group and the number of samples per subject in each group. The goal of the optimization is to determine the optimal sampling times in each group. This criterion is applied to a one-compartment open model with first-order absorption. The error model is either homoscedastic or heteroscedastic with constant coefficient of variation. Individual parameters are assumed to arise from a lognormal distribution with mean vectorMand covariance matrixC. Uncertainties about theMandCare accounted for by a prior distribution which is normal forMand Wishart forC. Sampling times are optimized by using a stochastic gradient algorithm. Influence of the number of different sampling schemes, the number of subjects per sampling schedule, the number of samples per subject in each sampling scheme, the uncertainties onMandCand the assumption about the error model and the dose have been investigated.

[1]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[2]  Eric Walter,et al.  Qualitative and quantitative experiment design for phenomenological models - A survey , 1990, Autom..

[3]  Jean-Marie Rocchisani,et al.  Comparison of ED, EID, and API Criteria for the Robust Optimization of Sampling Times in Pharmacokinetics , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[5]  L Pronzato,et al.  Optimal experiment design for nonlinear models subject to large prior uncertainties. , 1987, The American journal of physiology.

[6]  J. Kiefer,et al.  The Equivalence of Two Extremum Problems , 1960, Canadian Journal of Mathematics.

[7]  W. R. Buckland,et al.  Distributions in Statistics: Continuous Multivariate Distributions , 1973 .

[8]  D Z D'Argenio,et al.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.

[9]  William H. Press,et al.  Numerical Recipes in C, 2nd Edition , 1992 .

[10]  L. Sheiner,et al.  Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.

[11]  H. Kesten Accelerated Stochastic Approximation , 1958 .

[12]  Purdue Universit Stochastic Approximation Methods for Identification and Control-A Survey , 1974 .

[13]  E. Walter,et al.  Robust experiment design via stochastic approximation , 1985 .

[14]  P. Odell,et al.  A Numerical Procedure to Generate a Sample Covariance Matrix , 1966 .

[15]  L B Sheiner,et al.  Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.

[16]  David Z. D'Argenio,et al.  Optimal sampling times for pharmacokinetic experiments , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[17]  France Mentré,et al.  Sparse-Sampling Optimal Designs in Pharmacokinetics and Toxicokinetics* , 1995 .

[18]  Brian Whiting,et al.  Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[19]  E. Walter,et al.  Robust experiment design via maximin optimization , 1988 .

[20]  Ene I. Ette,et al.  Experimental Design and Efficient Parameter Estimation in Preclinical Pharmacokinetic Studies , 1995, Pharmaceutical Research.

[21]  B. Charpiat,et al.  How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporine , 1996, European Journal of Clinical Pharmacology.

[22]  France Mentré,et al.  The Use of Population Pharmacokinetics in Drug Development , 1996, Clinical pharmacokinetics.

[23]  Mats O. Karlsson,et al.  Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[24]  M Tod,et al.  Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. , 1996, Computer methods and programs in biomedicine.

[25]  A H Thomson,et al.  Bayesian Parameter Estimation and Population Pharmacokinetics , 1992, Clinical pharmacokinetics.

[26]  Jenny Wang,et al.  A computationally efficient approach for the design of population pharmacokinetic studies , 1992, Journal of Pharmacokinetics and Biopharmaceutics.